



A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis



Yunpeng Cai^a, Elena López-Ruiz^{a,b}, Jesper Wengel^c, Laura B. Creemers^d, Kenneth A. Howard^{a,*}

^a The Interdisciplinary Nanoscience Center (iNANO), Department of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus C, Denmark

^b Department of Health Sciences, University of Jaén, Jaén E-23071, Spain

^c Nucleic Acid Center, Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, 5230 Odense M, Denmark

^d Department of Orthopaedics, University Medical Center Utrecht, 3584 CX, Utrecht, Netherlands

ARTICLE INFO

Article history:

Received 7 December 2016

Received in revised form 2 March 2017

Accepted 3 March 2017

Available online 6 March 2017

Keywords:

Hyaluronic acid

Hydrogel

Osteoarthritis

CD44 receptor

Gapmer

Antisense

ABSTRACT

Hyaluronic acid (HA) is an attractive biomaterial for osteoarthritis (OA) treatment due to inherent functional and compatibility properties as an endogenous knee joint component. In this work, we describe a HA-based hydrogel with the dual functionality of increased CD44-dependent chondrocyte binding and controlled release of gapmer antisense oligonucleotides for unassisted cellular entry and subsequent gene silencing activity. A Schiff base-mediated gelation method was used to produce a panel of hydrogels varying in the aldehyde-modified HA (900 kDa) to chitosan ratios (3:7, 5:5 and 7:3) for identifying designs displaying optimal engagement of OA patient-derived CD44-expressing chondrocytes. Correlation was found between cell binding and CD44 expression, with maximal binding exhibited at a HA/chitosan ratio of 7:3, that was 181% higher than CD44-negative MCF-7 cell control cells. Transfection agent-free uptake into OA chondrocytes of fluorescent 13-mer DNA oligonucleotides with a flanked locked nucleic acid (LNA) gapmer design, in contrast to naked siRNA, was demonstrated by confocal and flow cytometric analysis. A sustained and complete release over 5 days was found with the 7:3 hydrogel, in contrast, the 5:5 and 3:7 hydrogel released 60% and 43% of loaded gapmers, respectively over the same period. A COX-2-specific gapmer designed with maximal chondrocyte gene silencing (~70% silencing efficiency at 500 nM compared with a mismatch gapmer sequence) resulted in effective COX-2 silencing over 14 days in hydrogels seeded with OA chondrocytes, with significant difference exhibited between day 3 and 10. This work introduces a novel HA-based CD44-mediated cellular binding and gapmer controlled release platform to modulate cellular gene expression.

© 2017 Elsevier B.V. All rights reserved.

1. Introduction

Osteoarthritis (OA) is a degenerative joint disorder that affects up to 50% of the US population over 50 years of age [1]. Currently no disease modifying treatments are available, and in end stage disease, arthroplasty is the only option. The synthetic activity of OA chondrocytes, which are the cellular components of the joint cartilage and considered to be terminally differentiated cells that maintain the extracellular matrix of the cartilage, is clearly increased but cannot counteract the ongoing catabolic processes [2].

Inflammation is thought to play a key role in the pain associated with OA and the induction of various extracellular matrix degrading

enzymes that leads to the cartilage tissue degradation are linked with aberrant expression of inflammation-related target genes such as cyclooxygenase-2 (COX-2) [3,4]. Maintaining the regenerative capacity of OA chondrocytes, whilst interrupting the production of inflammatory genes such as COX-2, is, therefore, an attractive therapeutic approach. Present anti-inflammatory treatments based on direct intra-articular injection of drugs such as corticosteroids only elicit short-term effects and are non-specific in action [5,6]. In this work we propose a strategy based on a drug releasing platform able to interact and increase therapeutic delivery into chondrocytes.

RNA interference-based post-transcriptional gene silencing with double stranded small interfering RNA (siRNA) offers the possibility of cytokine-specific reduction of activity, in contrast to global immunosuppression commonly associated with traditional anti-inflammatory drugs. The macromolecular size and polyanionic nature, however, requires delivery technologies such as cationic lipids or polymers to

* Corresponding author at: Interdisciplinary Nanoscience Center (iNANO), 8000 Aarhus C, Denmark.

E-mail address: kenh@inano.au.dk (K.A. Howard).

facilitate cellular entry, which necessitates careful design considerations to avoid toxicity [7]. Single stranded gapmer oligonucleotides are chimeric antisense oligonucleotides, containing a central block of deoxynucleotide monomers commonly flanked by locked nucleic acid (LNA) sequences that interrupt mRNA expression by induction of RNase H activation [8,9]. Significantly, the small size (11–13 nucleotides) allows unassisted cellular entry by gymnosis, without any requirement for a transfection agent. Moreover, fatty acid modifications of the gapmers have been shown to enhance the gene silencing efficiency, such as ω -6 polyunsaturated fatty acids and oleic acids [10].

The use of hydrophilic polymeric hydrogel drug releasing platforms is an attractive approach in OA due to combined flexible mechanical properties that can serve as scaffold for tissue regeneration and partly mimic the cartilage. Hyaluronic acid (HA) is an endogenous synovial fluid component that lowers frictional forces in the knee joint that has recently been applied in OA research [11–13]. An unexplored HA property in OA treatment, however, is the ability to utilize the specific binding properties of HA for the CD44 receptor [14,15] shown to be strongly expressed on bovine chondrocytes and normal human articular chondrocytes [16]. Previous work from our lab has demonstrated that the level of CD44 binding can be tuned by the HA molecular weight, with optimal engagement observed with high molecular weight HA [17] that offers a potential novel application using engineered HA hydrogel scaffolds for chondrocyte binding. This, combined with a capacity for sustained delivery of gapmers to inhibit COX-2 without the necessity of a transfection agent offers a novel dual functional platform for cartilage repair and interruption of damage progression.

In this work oxidized high molecular weight HA (900 kDa) was cross-linked with chitosan to form an *in situ* hydrogel by a Schiff reaction for CD44-mediated chondrocyte binding studies using CD44-expressing human primary chondrocytes and isogenic MCF-7 CD44-expressing and CD44-negative cells. An optimal COX-2 gapmer design identified in an *in vitro* screen were then loaded into the hydrogel to study the release profiles and subsequent anti-inflammation effects in IL-1 β induced OA chondrocytes over a 2-week period.

2. Materials and methods

2.1. Materials

Chitosan (degree of deacetylation > 90%, Mw 200–600 kDa) was purchased from Novamatrix, Sandvika, Norway. Hyaluronic acid (HA) (Mw 900 kDa) was purchased from Lifecore Biomedical, Chaska, USA, CyQuant cell proliferation kit from ThermoFisher Scientific, Waltham, USA and sodium periodate, *t*-butyl carbazate, β -glycerol phosphate disodium salt, ethylene glycerol, hyaluronidase and anti-CD44 FITC antibody from Sigma-Aldrich. Ultrapure water (Siemens Ultra Clear Basic plus) was used in all experiments.

COX-2 antisense oligonucleotides (ASOs) gapmer sequences used: Gapmer design 1: 5'-IGIGIAIT dGdCdCdAdGdTdGdAdTdA IGIAIGIG-3', Gapmer design 2: 5'-IGIGIAIT dGdCdCdAdGdTdGdA ITIAIGIA-3', palmitoylated gapmer design 3: 5'-IGIGIAaT dGdCdCdAdGdTdGdA aTIAIGIA-3', Gapmer design 4: 5'-IGIGIA dAdAdCdAdTdCdGdAdC IAIGIT-3'. Cy5 labelled gapmer: 5'-IGIGIAIT dGdCdCdAdGdTdTa IGIAIGIG-3', Cy5 labelled palmitoylated gapmer: 5'-IGIGIA aTdGdCdCdAdGdTdGdAaT IAIGIA, FAM labelled gapmer: 5'-IGIGIA dAdAdCdAdTdCdGdAdC IAIGIT-3' (I – locked nucleic acid, d – deoxyribonucleotide, a – palmitoylated amino locked nucleic acid). All ASO were synthesized as all-phosphorothioate linked sequences except for the Cy5 labelled palmitoylated gapmer which was synthesized as all-phosphodiester linked sequence. ASOs were dissolved in nuclease-free water (Ambion, Austin, TX) to 200 μ M concentrations measured by an Implen NanoDrop (Thermo Scientific, and stored at -20°C . siRNA was purchased from Genepharma (Shanghai, China) with the following sequences for the COX-2 siRNA-sense strand: 5'-CAUUCUUCCUUCGAAAUdTdT-3' and antisense strand: 5'-

AUUUCGAAGGAAGGGAAUGdTdT-3'. siRNA was diluted using nuclease-free water. The phosphoramidite building block used to incorporate the palmitoylated amino locked nucleic acid thymine monomer is commercially available from RiboTask ApS (www.ribotask.com).

Primary chondrocytes were isolated from articular cartilage of OA patients undergoing total knee arthroplasty. A CD44-negative MCF-7 cell line was derived from the original MCF-7 cell line (from ATCC) via subcloning after stable insertion of a sequence suitable for subsequent Flp-recombinase-mediated insertion of expression plasmids. These cells were used to insert the coding sequence (CDS) of the standard CD44 isoform 4 (NM_001001391.1; Consensus CDS CCDS31457.1) under the control of a constitutive cytomegalovirus promoter, to give the CD44-expressing cells [17].

2.2. Synthesis of aldehyde modified hyaluronic acid

Aldehyde-HA was synthesized by an oxidation method described previously [13]. Briefly, 1.0 g HA (2.5 mmol) was dissolved in 100 ml deionized water at a concentration of 10 mg/ml. 0.54 g sodium periodate (2.5 mmol) was dissolved in 5 ml deionized water and added dropwise into the HA solution under stirring in the dark. After 2 h, 1 ml of ethylene glycol was added into the reaction system to neutralize the excess amount of sodium periodate, and stirred for a further 1 h. The aldehyde-HA product was then dialyzed for 3 days against deionized water (changed daily) and then freeze-dried. The oxidation degree of HA was determined by a *t*-butyl carbazate method described previously [18].

2.3. Preparation of hyaluronic acid/chitosan hydrogels

200 mg chitosan was dissolved in 9 ml 0.1 M HCl solution, and then 1 ml of 560 mg β -glycerol phosphate solution added dropwise on ice, resulting in a chitosan solution at neutral pH [19]. Aldehyde-HA (HA) was dissolved in deionized water at a concentration of 20 mg/ml. Both the HA solution and chitosan solution were sterilized by UV irradiation before mixing. The hydrogel was prepared by mixing HA and chitosan solutions at different volume ratios (3:7, 5:5 and 7:3) and gelation initiated spontaneously upon mixing. The HA solution and chitosan solution were mixed in 24-well plate wells in a total volume of 500 μ l and incubated for 10 min to enable complete gelation. For gapmer incorporation, 4 nmol gapmers were first mixed with the HA solution, after which the HA/gapmer solution was mixed with the chitosan solution on ice.

2.4. Determination of CD44 expression in primary chondrocytes and isogenic MCF-7 cells

All cells were cultured at 37°C under 5% CO_2 in a water saturated atmosphere. For chondrocyte culture, Dulbecco's Modified Eagle's Medium (DMEM D6429) with 1% Penicillin-Streptomycin and 10% heat-inactivate foetal bovine serum was used. MCF-7 (passage 2–8) media was composed of DMEM Glutamax medium supplemented with foetal bovine serum (10%), Streptomycin/Penicillin (1%), insulin (10 $\mu\text{g ml}^{-1}$), and from the fourth day post plating the MCF-7, media was supplemented with hygromycin (120 $\mu\text{g ml}^{-1}$).

OA Chondrocytes and isogenic MCF-7 cells (CD44-expressing and CD44-negative) were seeded at 1×10^5 cells/well in a 12-well plate. The following day, cells were trypsinized and incubated with 5 μ l Anti-CD44 FITC antibody in 100 μ l blocking buffer (3% BSA in phosphate buffered saline (PBS) solution) for 30 min. After 3 times wash with blocking buffer, the cells were resuspended in PBS and the fluorescence intensity determined by flow cytometry using a Gallios (Beckman Coulter) flow cytometer with a 488 nm laser. The cell population gate was based on forward and side scattering, and was gated to distinguish dead cells and cell doublets. Events were set to 10,000 for each measurement and samples were in triplicate.

The fluorescent intensity of an anti-human CD44 fluorescent antibody using flow cytometry was used to determine the CD44 expression levels on the different cell types. CD44-negative MCF-7 cells did not show any antibody binding but the CD44-expressing MCF-7 showed CD44 expression (Supplementary Fig. 1). A 5.6-fold higher expression of CD44 was found in primary chondrocytes compared to the CD44-expressing MCF-7 cell line that supports the approach for CD44-dependent chondrocyte binding into an HA hydrogel matrix. This was investigated with the panel of cells seeded onto hydrogels ranging in

HA content. Overall chondrocyte viability was around 75–80% after 36 h incubation on the hydrogels (Supplementary Fig. 2). All the cell numbers of different cell types were normalized to the numbers of corresponding cells plated in wells to eliminate difference of cell proliferation rates. Significant differences in binding was found for OA chondrocytes than the CD44-expressing and CD44-negative MCF-7 cells (Fig. 1), with higher binding found with the higher CD44 expression. In the HA/chitosan 7:3 hydrogel, the chondrocyte normalized number was 181% higher than CD44-negative MCF-7 cells and 100% higher than low CD44-expressing MCF-7 cells, respectively. In the HA/chitosan 5:5 hydrogel, normalized chondrocytes number was 200% higher than CD44-negative MCF-7 cell, but normalized total chondrocyte number decreased by 34% compared with the 7:3 group. In the HA/chitosan 3:7 hydrogel, no significant difference of cell numbers was found between the cells differing in CD44 expression, which supports the cell number differences were attributed to the dependency on the CD44-HA interaction.

The ability of fluorescent labelled gapmer oligonucleotides to associate and enter OA chondrocytes without the requirement of a transfection agent was validated by flow cytometry and confocal microscopy (Fig. 2). Non-modified gapmers showed a 5-fold higher association compared with palmitoylated modified, whilst naked siRNA and non-treated group showed no fluorescent signals (Fig. 2). Treatment of 100 nM gapmers showed a higher cellular association with OA chondrocytes than 50 nM, 1.8-fold increase for non-modified gapmer and 1.75-fold increase for palmitoylated gapmer respectively. OA chondrocytes incubated for 24 h with either 50 or 100 nM gapmer showed green fluorescence throughout the cytoplasm that was absent from the nucleus (Fig. 2).

A panel of COX-2 specific gapmer designs of different sequences, with or without palmitoylation, were screened in OA chondrocytes for unassisted (without transfection agent) gene silencing compared to a COX-2 siRNA with lipofectamine transfection (Fig. 3). Successful silencing of target gene COX-2 (~82% silencing efficiency) was seen *in vitro* for the lipofectamine-mediated siRNA positive control. The silencing efficiency of different gapmer sequences were different dependent on design with gapmer design 1 (5'-IGIGIAIT dGdCdCdAdGdTdGdAdTdA IGIAIGIG-3') exhibited the highest silencing efficiency of 70% and gapmer design 3 was 33%. A 10-fold higher concentration was required for unassisted gapmer silencing compared with lipofectamine-mediated siRNA. It should be noted that exchange of two LNA nucleotides to gapmer design 2 with two palmitoylated amino-LNA nucleotides to give gapmer design 3, transforms an inactive ASO into an active one (gapmer design 3). Moreover, the four gapmers displayed a higher chondrocyte viability of 85–95% (92.3%, 94.2%, 88.5 and 84.6% respectively) compared with siRNA (73%) transfected with lipofectamine

evaluated by an MTT assay (Supplementary Fig. 3). Gapmer design 1 was used for subsequent experiments based on the *in vitro* cellular gene silencing screen.

Hydrogels at different HA: chitosan ratios were prepared to modulate the release profile of fluorescent gapmers measured by a fluorescent plate reader. Incorporation efficiency was 96.1–97.2%, with highest incorporation efficiency achieved with the hydrogel of HA/chitosan ratio of 7:3. A 5-day sustained release profile was shown with the HA-chitosan 7:3 hydrogel, while 5:5 hydrogel released over 3 days and 3:7 hydrogel within 1 day (Fig. 4). For the HA:chitosan 7:3 hydrogel, the total amount released was 101%, and for the 5:5 and the 3:7 hydrogels 60% and 43%, respectively. The initial burst in the first 4 h for the 7:3 hydrogel was 41%, whilst 5:5 and 3:7 hydrogels were 56% and 62%, respectively. No loss of structural integrity was observed after release over the 5 day period demonstrated by non-detection of fragment bands (Supplementary Fig. 4). The fainter band at day 5 can be attributed to the low amount released between day 4 and day 5.

A hydrogel containing a COX-2 specific gapmer design 1 exhibited a sustained COX-2 inhibition over 14 days. IL-1 β was used to induce inflammation in primary OA chondrocytes and increased the COX-2 level >100-fold compared with non-treated cells (Fig. 5). A second IL-1 β administration to OA chondrocytes at day 6 was performed to compensate for the loss of IL-1 β , as COX-2 level decreased to 49% at day 6 compared to day 1. From day 3, a significant reduction of COX-2 expression level was observed for the COX-2 gapmer treated cells, with silencing maintained up to day 10. At day 14, the COX-2 specific gapmer group COX-2 expression level increased to a similar level to the mismatch control group, most probably due to the completion of the COX-2 inhibition effect of the released gapmers.

4. Discussion

In this work, we introduce a novel HA-based hydrogel designed for the dual capacity for CD44-dependent chondrocyte binding and gene regulation for applications in the treatment of OA. The dual modality of chondrocytes engagement and simultaneous sustained release of gapmers for unassisted cellular entry, potentiates interaction between drugs and cells required for enhanced tissue regeneration within a biodegradable 3-dimensional scaffold.

Current use of HA in OA treatment is mainly focused on chondroprotection, anti-inflammatory and friction reduction [21,22]. HA-based hydrogels such as HA-fibrin [12], HA-chitosan [23] and methacrylated HA [24] hydrogels have been used for OA due to mechanical and biocompatibility properties as a natural component in knee joint. Typically, high molecular weight HA has been used to facilitate a more stable hydrogel matrix structure. There is also evidence showing the size of HA molecules and concentration are lower in OA patients with chronic or acute inflammation, and that the supply of high molecular weight HA can both stimulate the HA synthesis in synovium, and mediate chondrocyte proliferation and function [25].

To our knowledge no previous studies have utilized HA-based hydrogels for active CD44-mediated binding of chondrocytes as an approach for OA tissue repair, which was based on our previous finding of higher CD44 engagement with high 900 kDa molecular weight HA [17]. Although it is termed as 'binding' in this work, and cell movement into hydrogel was not investigated in the present study, CD44 interactions may lead to active recruitment of chondrocytes into the porous network of the hydrogel. A previous study has reported the use of hydrogel immobilized CD34 antibody to capture endothelial progenitor cells by utilizing receptor binding [26]. Incorporation of labile biomacromolecules such as antibodies as a method for cell binding or recruitment, however, is restricted by the necessity for conjugation and stability. The preferential binding of surrounding cells into a drug-containing 3-D matrix offers great potential in tissue regeneration applications as an alternative to loading patient-specific chondrocytes into the hydrogels before implantation that requires patient cell harvest.




Fig. 1. Cellular binding to hydrogels composed of different HA: chitosan ratios (7:3, 5:5 and 3:7). Chondrocytes, CD44-expressing and CD44-negative MCF-7 cells were seeded on hydrogels and incubated for 36 h. After 3 × PBS wash, binding cell numbers were determined and normalized to attached cell numbers in plate wells (N = 3). Asterisk denotes statistical significance.




Fig. 2. Cellular uptake of fluorescence-labelled gapmer oligonucleotides in primary OA chondrocytes. Cy5 labelled gapmers (50 and 100 nM), with and without palmitoylation, were incubated with primary OA chondrocytes for 24 h, and fluorescence intensity determined using flow cytometry. Naked Cy5 labelled siRNA at a concentration of 50 nM was used as a negative control. Flow cytometer was determined with a laser wavelength of 633 nm and gate events of 10,000 ($N = 3$). Insert: Left panel shows primary OA chondrocytes with 50 nM gapmer without palmitoylation, and right panel shows primary OA chondrocytes with 100 nM gapmer without palmitoylation. Nuclei were stained with Hoechst (blue), actin filaments were stained with phalloidin (red) and gapmer were labelled with FAM (green). Original magnification 20 \times .

Previous reports have suggested the role of HA in the recruitment of CD44-expressing cancer cells in endogenous extracellular matrix possibly due to HA presence [27,28]. However, there are no reports on CD44-expressing chondrocyte binding to HA-rich matrix and the application for OA treatment.

In our work the HA was modified for introduction of aldehyde groups to allow cross-linking with the carboxyl-bearing chitosan. The gelation process took ~2 min, suggesting potential use as an injectable soluble formulation in the joint for *in situ* gelation. An important consideration was to retain the HA conformation that allows effective interaction with CD44 that has previously been reported to be dependent on three carboxyl groups [29]. For instance, a 50 mol% HA modification of adipic acid dihyrazide has been shown to not bind CD44 [30]. In our work, a higher primary chondrocyte number, compared to the CD44-expressing and CD44-negative cell line, was shown with increased

900 kDa HA content that is most probably attributed to the higher CD44-expression level determined in these cells. The isogenic MCF-7 cells were used as models to study HA-CD44 specific binding, so differences could be attributed to CD44 expression level only, with the CD44-expressing cells, in contrast to the CD44-negative MCF-7 cells, exhibiting a higher binding with a HA-rich matrix.

The hydrogel was used to incorporate the polyanionic gapmers of ~6 kDa molecular weight. To our knowledge, this is the first demonstration of incorporation and sustained release of gapmers from a HA-based 3-D scaffold. The hydrogel is a highly water-containing matrix that allows loaded small hydrophilic molecules to diffuse into the outer aqueous environment at a relatively rapid speed [31]. It is, therefore, unlikely that gapmers were physically entrapped within the matrix, but rather incorporated by electrostatic interactions between the phosphate backbone of the gapmer and the amino-bearing chitosan, that result in a




Fig. 3. COX-2 cellular gene *in vitro* using different gapmer oligonucleotide designs in primary OA chondrocytes. Primary OA chondrocytes were treated with 500 nM gapmers of different designs. After 24 h incubation, 10 ng/ml IL-1 β was added to induce inflammation. After 4 days incubation, the RNA was extracted for real time PCR analysis to determine COX-2 gene expression levels. COX-2 siRNA with lipofectamine 2000 was used as a positive control at a concentration of 50 nM. ($N = 3$). Gapmer design 1: 5'-IGIGIAIT dGdCdCdAdGdTdGdA ITAIGIA-3', Gapmer 2 design: 5'-IGIGIAIT dGdCdCdAdGdTdGdA ITAIGIA-3', Gapmer 3 design: 5'-IGIGIAaT dGdCdCdAdGdTdGdA aTIAIGIA-3', Gapmer design 4: 5'-IGIGIA dAdAdCdAdTdTdCdAdC IAIGIT-3'. (I – locked nucleic acid, d – deoxyribonucleotide, a – palmitoylated amino locked nucleic acid.) COX-2 siRNA-sense strand: 5'-CAUUCUCCUCCUCCGAAAUdTdT-3' and antisense strand: 5'-AUUUCGAAGGAAGGAAUGdTdT-3'.




Fig. 4. Accumulative release profiles of gapmer oligonucleotides in different hydrogel compositions. Cy5 labelled gapmer (50 μ g) was incorporated into hydrogels composed of different HA:chitosan ratios (7:3, 5:5 and 3:7). 2 ml hydrogel was added into a 24-well plate and 0.5 ml PBS was used as release media. Fluorescence intensity of media was determined at an excitation wavelength of 650 nm and emission wavelength of 670 nm. Released gapmer amount was calculated using a standard calibration curve. ($N = 3$).

high encapsulation efficiency of ~96.1–97.2%. The release of gapmers can be attributed to the exchange of polyanions in the culture medium, which may occur in an *in vivo* environment due to anionic peptides or chloride ions in body fluids. The hydrogel with the highest HA percentage of 70% displayed a more complete release and lower initial burst than the other compositions. This could be attributed to the tighter binding of the gapmers with higher chitosan contents, restricting release prior to hydrogel degradation, which may take >1 month [32]. The HA: chitosan 7:3 hydrogel was selected for subsequent silencing studies due to its favourable gapmer release profile and high chondrocyte binding.

The attractive properties of gapmers are specificity, stability and ability for unassisted cellular entry by the process of gymnosis to facilitate gene silencing. Gymnosis is the process of the cellular delivery of




Fig. 5. COX-2 cellular gene expression level from 1 to 14 days in primary OA chondrocytes below gapmer oligonucleotide loaded hydrogels. COX-2 gapmers were incorporated in a HA-based hydrogel (HA:chitosan of 7:3). Primary OA chondrocytes were treated with 10 ng/ml IL-1 β to induce inflammation at day 0 and 6 (arrows). At different time points, RNA was extracted for real time PCR analysis. COX-2 expression levels were normalized to non-treated groups. A hydrogel loaded with a mismatch gapmer sequence was used as negative control. Asterisk denotes significant differences between experimental and negative control groups ($N = 3$).

antisense oligodeoxynucleotides to cells, in the absence of any carriers or conjugation, that produces sequence-specific gene silencing [10]. This abrogates transfection agent inclusion and makes gapmers suitable for sustained release and subsequent entry into surrounding cells. Several gapmer designs were screened to select designs showing maximal COX-2 cellular gene silencing for downstream hydrogel studies. Palmitoylated gapmers were expected to have higher cellular uptake due to the hydrophobic property of fatty acid that can bind to the cell membrane via hydrophobic interaction. However, it showed less uptake and silencing efficiency compared with the optimal non-modified gapmer. This could, among other factors, be due to different nucleotide sequence and LNA number between the two gapmers investigated. As well as it being a saturated fatty acid derivative, in contrast to unsaturated fatty acid shown previously to enhance gene silencing [10].

COX-2 is one of the main inflammatory targets in OA, and IL-1 β has been widely used to induce inflammation in the OA model [33]. The COX-2 level is increased greatly by IL-1 β compared with chondrocytes from healthy knee joints. For OA treatment, COX-2 inhibitor drugs has become the most commonly prescribed treatment to relieve pain and slow the cartilage breakdown process [34]. In the COX-2 inhibition with gapmer loaded HA hydrogel experiment, COX-2 silencing effects were not apparent at day 1 after induction of inflammation using IL-1 β . This may be due to time required for cellular uptake and mRNA gene silencing process and mRNA half-life. The unassisted delivery of gapmer relies on a passive diffusion process and requires time to reach an effective concentration in the cytoplasm for mRNA cleavage [35], whilst the existing COX-2 mRNA requires time for degradation as mRNA has an approximate half-life of 7.1 h [36]. Results showed a 14-day COX-2 silencing effect despite a 5-day release profile, which can be attributed to the stability of gapmers in the cellular cytoplasm. Gapmers are flanked by locked nucleic acid modification, that give protection from endogenous enzymatic degradation, and, thus, can exert silencing for an extended period that has been shown previously to be 6–10 days [9]. In our work, the prolonged silencing effect was extended over 10 to 14 days, suggesting the hydrogel-mediated delivery was effective for prolonged gene silencing. Compared with current nonsteroidal anti-inflammatory drugs for OA treatment which are orally taken several times daily and may have gastrointestinal adverse reactions [37], the local sustained release of COX-2 gapmer may reduce drug dose frequency and minimize systemic toxicity. The oxidized hyaluronic acid and chitosan solutions have low viscosity, which should not present a problem as injectables for future *in vivo* studies. It is, however, not possible to inject the combined HA/chitosan mix due to the fast gelation of ~10 s. Simultaneous injections, however, of the two solutions is possible using a two compartment syringe to allow gelation *in situ*. A higher number of chondrocytes have been used (10–130 million cells/ml) in the literature for *in vitro* tissue regeneration applications [38] than used in our experiment (1×10^5 cells/well), however, the actual chondrocyte number in cartilage is ~14,000 cells/mm³ [39], which equates to ~14 million cells/ml. The demonstrated CD44-mediated engagement with the hydrogel in this work suggests potential recruitment of chondrocytes that potentiates therapeutic delivery into cells. Moreover, we do not anticipate that increasing the dose of gapmers would be a problem. The mechanism driven by electrostatic incorporation into the hydrogel should allow higher levels of gapmer to be incorporated due to excess polycationic chitosan compared to the polyanionic gapmers used.

In this work, COX-2 was the silencing target for inhibition of inflammation. Other gapmers targeting different targets such as aggrecan degradation protease ADAMTS5 (A disintegrin and metalloproteinase with thrombospondin motifs 5) can intervene in the cartilage breakdown pathway [40] and are a current focus of our work.

In this study, we introduce a novel HA-hydrogel containing gapmer antisense oligonucleotides that has a dual modality of chondrocyte binding and gene silencing. A 5-day sustained release of COX-2 specific gapmers resulted into a 14-day COX-2 silencing effect in OA chondrocytes. The combined properties of chondrocyte binding, release and unassisted cellular entry of target-specific gapmers promotes this

delivery platform for a wide panel of targets that are key regulators in OA.

Acknowledgements

The authors thank Jan Mollenhauer (Lundbeckfonden Center of Excellence NanoCAN, Institute of Molecular Medicine, University of Southern Denmark) for providing CD44-expressing and CD44-negative MCF-7 cells. This project has received funding from the European Union's Horizon 2020 research and innovation programme under Marie Skłodowska-Curie grant agreement No. 642414. Laura B. Creemers is supported by the Dutch Arthritis Foundation (LLP12).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.jconrel.2017.03.004>.

References

- [1] K. Brandt, M. Doherty, L. Lohmander, Composition and Structure of Articular Cartilage, Osteoarthritis, Oxford University Press Inc, New York, 1998 110–111.
- [2] M.B. Goldring, The role of the chondrocyte in osteoarthritis, *Arthritis Rheum.* 43 (2000) 1916–1926.
- [3] F. Berenbaum, F. Eymard, X. Houard, Osteoarthritis, inflammation and obesity, *Curr. Opin. Rheumatol.* 25 (2013) 114–118.
- [4] M.B. Goldring, M. Otero, Inflammation in osteoarthritis, *Curr. Opin. Rheumatol.* 23 (2011) 471.
- [5] J.P. Raynaud, C. Buckland-Wright, R. Ward, D. Choquette, B. Haraoui, J. Martel-Pelletier, I. Uthman, V. Khy, J.L. Tremblay, C. Bertrand, Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial, *Arthritis Rheum.* 48 (2003) 370–377.
- [6] L. Dai, X. Zhang, X. Hu, Q. Liu, Z. Man, H. Huang, Q. Meng, C. Zhou, Y. Ao, Silencing of miR-101 prevents cartilage degradation by regulating extracellular matrix-related genes in a rat model of osteoarthritis, *Mol. Ther.* 23 (2015) 1331–1340.
- [7] K.A. Howard, Delivery of RNA interference therapeutics using polycation-based nanoparticles, *Adv. Drug Deliv. Rev.* 61 (2009) 710–720.
- [8] C. Wahlestedt, P. Salmi, L. Good, J. Kela, T. Johnsson, T. Hökfelt, C. Broberger, F. Porreca, J. Lai, K. Ren, Potent and nontoxic antisense oligonucleotides containing locked nucleic acids, *Proc. Natl. Acad. Sci. USA* 97 (2000) 5633–5638.
- [9] H.S. Soifer, T. Koch, J. Lai, B. Hansen, A. Hoeg, H. Oerum, C. Stein, Silencing of gene expression by gymnotic delivery of antisense oligonucleotides, *Funct. Genomics Methods Protocols* (2012) 333–346.
- [10] N. Souleimanian, G.F. Deleavey, H. Soifer, S. Wang, K. Tiemann, M.J. Damha, C.A. Stein, Antisense 2'-deoxy, 2'-fluoroarabino nucleic acids (2' F-ANAs) oligonucleotides: in vitro gymnotic silencers of gene expression whose potency is enhanced by fatty acids, *Mol. Ther. Nucl. Acids* 1 (2012), e43.
- [11] R. Barbucci, S. Lamponi, A. Borzacchiello, L. Ambrosio, M. Fini, P. Torricelli, R. Giardino, Hyaluronic acid hydrogel in the treatment of osteoarthritis, *Biomaterials* 23 (2002) 4503–4513.
- [12] T.N. Snyder, K. Madhavan, M. Intrator, R.C. Dregalla, D. Park, A fibrin/hyaluronic acid hydrogel for the delivery of mesenchymal stem cells and potential for articular cartilage repair, *J. Biol. Eng.* 8 (2014) 1.
- [13] H. Tan, C.R. Chu, K.A. Payne, K.G. Marra, Injectable in situ forming biodegradable chitosan–hyaluronic acid based hydrogels for cartilage tissue engineering, *Biomaterials* 30 (2009) 2499–2506.
- [14] A. Aruffo, I. Stamenkovic, M. Melnick, C.B. Underhill, B. Seed, CD44 is the principal cell surface receptor for hyaluronate, *Cell* 61 (1990) 1303–1313.
- [15] R.J. Peach, D. Hollenbaugh, I. Stamenkovic, A. Aruffo, Identification of hyaluronic acid binding sites in the extracellular domain of CD44, *J. Cell Biol.* 122 (1993) 257–264.
- [16] O. Ishida, Y. Tanaka, I. Morimoto, M. Takigawa, S. Eto, Chondrocytes are regulated by cellular adhesion through CD44 and hyaluronic acid pathway, *J. Bone Miner. Res.* 12 (1997) 1657–1663.
- [17] M.F. Ebbesen, M.T. Olesen, M.C. Gjelstrup, M.M. Pakula, E.K. Larsen, I.M. Hansen, P.L. Hansen, J. Mollenhauer, B.M. Malle, K.A. Howard, Tunable CD44-specific cellular retargeting with hyaluronic acid nanoshells, *Pharm. Res.* 32 (2015) 1462–1474.
- [18] K.H. Bouhadir, D.S. Hausman, D.J. Mooney, Synthesis of cross-linked poly (aldehyde guluronate) hydrogels, *Polymer* 40 (1999) 3575–3584.
- [19] S. Nair, N. Remya, S. Remya, P.D. Nair, A biodegradable in situ injectable hydrogel based on chitosan and oxidized hyaluronic acid for tissue engineering applications, *Carbohydr. Polym.* 85 (2011) 838–844.
- [20] C. Jarry, J.-C. Leroux, J. Haec, C. Chaput, Irradiating or autoclaving chitosan/polyol solutions: effect on thermogelling chitosan–BETA-glycerophosphate systems, *Chem. Pharm. Bull.* 50 (2002) 1335–1340.
- [21] R.D. Altman, A. Manjoo, A. Fierlinger, F. Niazi, M. Nicholls, The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review, *BMC Musculoskelet. Disord.* 16 (2015) 1.
- [22] R.R. Bannuru, E.E. Vaysbrot, M.C. Sullivan, T.E. McAlindon, Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis, *Semin. Arthritis Rheum.* 43 (2014) 593–599.
- [23] H. Park, B. Choi, J. Hu, M. Lee, Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering, *Acta Biomater.* 9 (2013) 4779–4786.
- [24] I.E. Erickson, A.H. Huang, S. Sengupta, S. Kestle, J.A. Burdick, R.L. Mauck, Macromer density influences mesenchymal stem cell chondrogenesis and maturation in photocrosslinked hyaluronic acid hydrogels, *Osteoarthr. Cartil.* 17 (2009) 1639–1648.
- [25] L.W. Moreland, Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action, *Arthritis Res. Ther.* 5 (2003) 1.
- [26] G. Camci-Unal, H. Aubin, A.F. Ahari, H. Bae, J.W. Nichol, A. Khademhosseini, Surface-modified hyaluronic acid hydrogels to capture endothelial progenitor cells, *Soft Matter* 6 (2010) 5120–5126.
- [27] O. Nagano, H. Saya, Mechanism and biological significance of CD44 cleavage, *Cancer Sci.* 95 (2004) 930–935.
- [28] I. Okamoto, Y. Kawano, H. Tsuiki, J.-i. Sasaki, M. Nakao, M. Matsumoto, M. Suga, M. Ando, M. Nakajima, H. Saya, CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration, *Oncogene* 18 (1999) 1435–1446.
- [29] S. Banerji, A.J. Wright, M. Noble, D.J. Mahoney, I.D. Campbell, A.J. Day, D.G. Jackson, Structures of the Cd44–hyaluronan complex provide insight into a fundamental carbohydrate–protein interaction, *Nat. Struct. Mol. Biol.* 14 (2007) 234–239.
- [30] K.S. Kim, S. Kim, S. Beack, J.-A. Yang, S.H. Yun, S.K. Hahn, In vivo real-time confocal microscopy for target-specific delivery of hyaluronic acid–quantum dot conjugates, *Nanomed. Nanotechnol. Biol. Med.* 8 (2012) 1070–1073.
- [31] T.R. Hoare, D.S. Kohane, Hydrogels in drug delivery: progress and challenges, *Polymer* 49 (2008) 1993–2007.
- [32] J. Patterson, R. Siew, S.W. Herring, A.S. Lin, R. Guldberg, P.S. Stayton, Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration, *Biomaterials* 31 (2010) 6772–6781.
- [33] E. Hedbom, H. Häuselmann, Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation, *Cell. Mol. Life Sci.* 59 (2002) 45–53.
- [34] R. Bannuru, J. Wong, D. Kent, C. Schmid, T. McAlindon, Intra-articular corticosteroids may be a cost-effective strategy for short-term management of knee osteoarthritis, *Osteoarthr. Cartil.* 23 (2015) A392–A394.
- [35] C. Stein, J.B. Hansen, J. Lai, S. Wu, A. Voskresenskiy, A. Høg, J. Worm, M. Hedtjärn, N. Souleimanian, P. Miller, Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents, *Nucleic Acids Res.* 38 (2010) e3.
- [36] I.V. Sharova, A.A. Sharov, T. Nedorezov, Y. Piao, N. Shaik, M.S. Ko, Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells, *DNA Res.* 16 (2009) 45–58.
- [37] R. Chou, M.S. McDonagh, E. Nakamoto, et al., Analgesics for Osteoarthritis[J], Comparative Effectiveness Reviews, No. 38 (2011).
- [38] R. Mauck, C.-B. Wang, E. Oswald, G. Ateshian, C. Hung, The role of cell seeding density and nutrient supply for articular cartilage tissue engineering with deformational loading, *Osteoarthr. Cartil.* 11 (2003) 879–890.
- [39] R. Stockwell, The interrelationship of cell density and cartilage thickness in mammalian articular cartilage, *J. Anat.* 109 (1971) 411.
- [40] S.S. Glasson, R. Askew, B. Sheppard, B. Carito, T. Blanchet, H.-L. Ma, C.R. Flannery, D. Peluso, K. Kanki, Z. Yang, Deletion of active ADAMT5 prevents cartilage degradation in a murine model of osteoarthritis, *Nature* 434 (2005) 644–648.